Related by context. All words. (Click for frequent words.) 74 prostate cancer CaP 73 breast carcinoma 71 ovarian carcinoma 71 cervical carcinoma 71 PCa 70 operable breast cancer 70 HNSCC 69 prostate cancer PCa 68 CIN3 68 ductal breast cancer 68 colorectal cancer CRC 68 urothelial carcinoma 68 ASCUS 68 pancreatic adenocarcinoma 68 pCR 68 urothelial bladder cancer 68 clinically localized prostate 67 HGPIN 67 atypical hyperplasia 67 HER2 positive cancers 67 advanced neoplasia 67 lymphocytosis 67 serous ovarian cancer 67 grade cervical intraepithelial 67 CIN2 + 67 colorectal carcinoma 67 invasive carcinoma 67 node metastases 67 epithelial ovarian 67 basal cell carcinoma BCC 66 seminoma 66 nonmetastatic 66 metastatic renal cell carcinoma 66 neoplasia 66 histologically confirmed 66 endometrial carcinoma 66 prostate carcinoma 66 lymphadenectomy 66 cervical intraepithelial neoplasia 66 cytologic 66 locoregional 66 HER2 expression 66 advanced adenomas 66 histologic subtype 66 neoadjuvant chemotherapy 66 advanced adenoma 66 endometrial cancers 66 colorectal adenoma 66 nodal metastasis 65 urothelial cancer 65 chlamydial infection 65 relapsed ovarian cancer 65 localized renal 65 gastric carcinoma 65 GnRH agonists 65 histological subtype 65 Adjuvant chemotherapy 65 specific antigen PSA 65 peritoneal carcinomatosis 65 lobular breast cancer 65 HER2 overexpression 65 relapsed MM 65 BRCA2 mutation carriers 65 ADPKD 65 CC genotype 65 lobular carcinoma 65 colorectal neoplasms 65 distant metastasis 65 Radical prostatectomy 65 ductal carcinomas 65 abnormal cytology 65 PSA nadir 65 antigen PSA 65 BRCA mutation carriers 65 mammographic density 65 neoadjuvant 65 lymph node metastasis 65 polycystic ovary syndrome PCOS 65 TT genotype 65 cutaneous melanoma 65 ovarian malignancy 65 spontaneous preterm birth 65 peritoneal cancer 65 recurrent ovarian cancer 64 HER2 positive breast cancer 64 tumor histology 64 endometrial hyperplasia 64 pelvic lymphadenectomy 64 deCODE BreastCancer TM 64 fallopian tube carcinoma 64 GISTs 64 IV NSCLC 64 pT2 64 medically inoperable 64 mRCC 64 precancerous cervical lesions 64 total thyroidectomy 64 urolithiasis 64 recurrent endometrial cancer 64 prospectively randomized 64 nonsmall cell lung cancer 64 epithelial tumors 64 precursor lesions 64 macroalbuminuria 64 malignant pleural mesothelioma 64 neoplasias 64 T1a 64 recurrent ovarian 64 biochemical relapse 64 FDG-PET/CT 64 recurrent glioblastoma multiforme 64 castrate resistant prostate cancer 64 pT3 64 tumor subtypes 64 cytoreduction 64 ErbB2 positive 64 nodal metastases 64 metastatic prostate cancer 64 metastatic gastric 64 prostate adenocarcinoma 64 invasive ductal 64 SLNB 64 malignant nodules 64 axillary dissection 64 curative resection 64 hepatocellular carcinomas 64 radical prostatectomy RP 64 superficial bladder cancer 63 lobular cancer 63 BRCA1 mutation carriers 63 BRCA mutations 63 renal cell carcinomas 63 invasive lobular carcinoma 63 differentiated thyroid 63 cardiac troponin T 63 stage IIIB 63 tumor recurrence 63 invasive carcinomas 63 situ LCIS 63 NMIBC 63 renal tumors 63 atypia 63 leiomyomas 63 grade cervical dysplasia 63 adenocarcinomas 63 colorectal liver metastases 63 adjuvant radiation 63 hematopoietic cancers 63 chemoradiotherapy 63 EBRT 63 cytoreductive nephrectomy 63 aromatase inhibitors AIs 63 recurrent NSCLC 63 carotid stenosis 63 prognostic variables 63 hormone refractory 63 K ras mutations 63 HIV HCV coinfected 63 thyroid carcinoma 63 HER2 negative 63 cervical lesions 63 thyroglobulin 63 AST ALT 63 cTnI 63 squamous cell lung cancer 63 adjuvant chemotherapy 63 Adjuvant therapy 63 leukemia AML 63 chemosensitivity 63 gastric adenocarcinoma 63 R0 resection 63 resectable 63 urine cytology 63 systemic lupus erythematosus SLE 63 preoperative PSA 63 hepatocellular carcinoma HCC 63 neoadjuvant therapy 63 Doxil ® 63 refractory prostate cancer 63 distant metastases 63 KRAS status 63 ductal cancer 63 CaP 63 thyroid nodules 63 Epithelial ovarian cancer 62 endocrine therapies 62 postoperative AF 62 adenomatous polyps 62 mucinous 62 Heavy menstrual bleeding 62 axillary lymph nodes 62 breast carcinomas 62 IV melanoma 62 atypical ductal hyperplasia 62 undergoing radical prostatectomy 62 HER2 positive metastatic breast 62 chemoresistant 62 dysplastic nevi 62 gefitinib Iressa 62 adjuvant therapy 62 ovarian tumors 62 T2DM 62 virologic response 62 metastatic RCC 62 HBsAg 62 lymph node metastases 62 recurrent VTE 62 LHRH receptor positive 62 diabetes mellitus DM 62 non squamous NSCLC 62 adenoma 62 transurethral resection 62 biochemical recurrence 62 taxane chemotherapy 62 metastatic lymph nodes 62 hepatorenal syndrome 62 Papillary 62 postoperative chemotherapy 62 serum PSA 62 adjuvant radiotherapy 62 SUVmax 62 stratifying patients 62 androgen deprivation 62 dysglycemia 62 microwave hyperthermia 62 malignant lymphoma 62 PSADT 62 Bezielle 62 HER2 gene 62 refractory ovarian cancer 62 PCNSL 62 adnexal mass 62 locoregional recurrence 62 carcinoid tumor 62 bladder carcinoma 62 prognostic biomarker 62 diffuse gastric 62 CMV disease 62 carcinoid 62 EUS FNA 62 baseline LDH 62 mCRC patients 62 resistant ovarian cancer 62 Malignant Melanoma 62 androgen ablation 62 localized prostate cancer 62 liver metastasis 62 immunohistochemical staining 62 MetS 62 ovarian cancer 62 paragangliomas 62 postoperative complication 62 lymph node dissection 62 colorectal neoplasia 62 heavily pretreated 62 NSCLC 62 lymph node involvement 62 SLN biopsy 62 #.#ng/ml 62 squamous cell carcinoma SCC 61 polyp recurrence 61 HER2 + 61 estrogen receptor ER 61 breast lesions 61 invasive breast cancer 61 Androgen deprivation therapy 61 nasopharyngeal carcinoma 61 thyrotropin 61 squamous intraepithelial lesions 61 KRAS mutation 61 Stage IIB 61 Prognostic factors 61 malignant ovarian 61 cranial irradiation 61 hormone receptor status 61 p# biomarker 61 trastuzumab Herceptin ® 61 Trichomonas vaginalis 61 neutrophil count 61 CIN2 61 prognostic indicators 61 prostate cancer CRPC 61 BRCA gene mutation 61 cisplatin chemotherapy 61 Prostate specific antigen 61 nonmelanoma skin cancers 61 recurrent metastatic 61 F FDG PET 61 cisplatin resistant 61 KRAS mutations occur 61 precancerous cervical 61 antigen PSA levels 61 pg ml 61 liposomal amphotericin B 61 recurrent venous thromboembolism 61 adjuvant tamoxifen 61 debulking surgery 61 invasive lobular 61 HER2 positive 61 underwent surgical resection 61 hormone receptor positive 61 undergone radical prostatectomy 61 malignant lesions 61 metastatic colorectal 61 LV dysfunction 61 iPTH 61 multivariate Cox 61 premenopausal 61 bladder cancers 61 metachronous 61 oophorectomy 61 antibody titer 61 bone metastasis 61 cholangiocarcinoma 61 pulmonary metastases 61 liver resection 61 mg/m2 dose 61 hepatitis C genotype 61 underwent resection 61 nonalcoholic steatohepatitis NASH 61 endocrine therapy 61 neoadjuvant treatment 61 B7 H3 61 cTnT 61 papillary renal cell carcinoma 61 contralateral breast cancer 61 pheochromocytoma 61 progesterone receptor negative 61 Hodgkin lymphoma HL 61 glomerular filtration 61 pelvic malignancies 61 sarcomatoid 61 colorectal adenomas 61 severe neutropenia 61 tPSA 61 leukocyte count 61 neoplasia PIN 61 neoplasm 61 hamartomas 61 underwent radical prostatectomy 61 papillary thyroid carcinoma 61 systolic dysfunction 61 subclinical atherosclerosis 61 transthyretin amyloidosis 61 % CI #.#-#.# [003] 61 ICD implantation 61 acute leukemias 61 MammaPrint R 61 symptomatic BPH 61 Gleevec resistant 61 radioiodine therapy 61 carotid plaques 61 cytoreductive surgery 61 HER2 receptor 61 alanine aminotransferase ALT 61 BRCA mutation 61 metastatic malignant melanoma 61 Endometrial 61 metastatic malignant 61 fibroadenomas 61 adenoma recurrence 61 intact parathyroid hormone 61 secondary hyperparathyroidism 61 prostate cancer HRPC 61 renal carcinoma 61 adnexal masses 61 serum phosphate 61 radical cystectomy 61 nonmetastatic prostate cancer 61 histologically proven 61 DFMO 61 intestinal metaplasia 61 definite stent thrombosis 61 paroxysmal AF 61 ER CHOP 61 metastatic ovarian cancer 61 Anaplastic 61 immunohistochemical 61 IgA deficiency 61 taxane therapy 61 antiangiogenic therapy 60 castrate resistant 60 Endometrial cancer 60 grade gliomas 60 adrenalectomy 60 serum thyroglobulin 60 artery embolization 60 gastric cardia 60 pmol L 60 KRAS mutations 60 independent prognostic marker 60 Lymph node 60 hepatocellular cancer 60 Aspergillus infections 60 serum IGF 60 HBeAg seroconversion 60 AGHD 60 NNRTI resistance 60 HER2 positivity 60 sentinel lymph node biopsy 60 platinum refractory 60 octreotide LAR 60 metastatic lung cancer 60 transrectal ultrasound guided 60 immunostaining 60 prognostic indicator 60 external beam radiotherapy 60 BRCA1 BRCA2 60 endometrioid 60 testicular germ cell 60 plasma uric acid 60 receptor tyrosine kinase inhibitor 60 androgen independent 60 BCR ABL mutations 60 radical nephrectomy 60 IL#B 60 CP CPPS 60 retrospective cohort 60 luteal 60 micrometastases 60 angiographically 60 ovulation induction 60 chemotherapy cisplatin 60 situ CIS 60 extracapsular extension 60 viral kinetics 60 CrCl 60 natriuretic peptide 60 #F FDG PET 60 surgical debulking 60 recurrent miscarriage 60 surgically resectable 60 beta blocker therapy 60 Sentinel node biopsy 60 perioperative morbidity 60 extracolonic findings 60 paricalcitol 60 Adenomas 60 Hurthle cell 60 hepatocellular carcinoma 60 preoperative chemotherapy 60 plasma folate 60 esophageal squamous cell carcinoma 60 Toxicities 60 postpartum hemorrhage 60 T1c 60 BRCA2 mutations 60 Surgical resection 60 bladder tumors 60 thrombophilia 60 EGFR mutation 60 neovascular 60 C. trachomatis 60 radiotherapy RT 60 haematological toxicity 60 thromboembolic disease 60 obstructive coronary artery 60 vasomotor symptoms 60 benign prostatic hypertrophy 60 serum urate levels 60 acute promyelocytic leukemia 60 rFSH 60 colorectal polyp 60 polyp detection 60 mutated KRAS 60 dasatinib Sprycel 60 biliary tract cancer 60 osteopenic 60 CMV infection 60 NSCLC tumors 60 AAT deficiency 60 EGFR tyrosine kinase inhibitors 60 intracranial hemorrhage ICH 60 pancreatic carcinoma 60 glycated hemoglobin levels 60 serum ALT 60 Mitomycin C 60 hepatic metastases 60 thymoma 60 testicular cancers 60 unresectable tumors 60 thiopurine 60 invasive aspergillosis 60 BCG refractory 60 asymptomatic carotid stenosis 60 grade squamous intraepithelial 60 gynecologic malignancy 60 microscopic hematuria 60 ultrasonographic 60 testicular tumors 60 liver metastases 60 LHRH agonist 60 thromboembolic events 60 LTBI 60 micrometastasis 60 axillary lymph node 60 HCV antibody 60 virologic failure 60 grade glioma 60 platelet reactivity 60 invasive cervical cancer 60 estrogen receptor negative 60 invasive candidiasis 60 trabectedin 60 lung metastases 60 IFN beta 60 pancreatic NET 60 thyroid stimulating hormone 60 breast cancer recurrence 60 polycythemia vera PV 60 recurrent epithelial ovarian 60 anti JCV antibodies 60 GnRH agonist 60 serum prostate 60 autoantibody positive 60 FDG uptake 60 choriocarcinoma 60 histopathologic 60 Hepatocellular Carcinoma HCC 60 ALCL 60 HBeAg negative 60 K#N 60 chemoradiation 60 diagnostic biomarker 60 acute GvHD 60 renal cell carcinoma 60 malignant polyps 60 renal biopsy 60 imatinib Gleevec 60 metastatic bladder 60 gadolinium enhanced 60 CHEK2 60 % CI #.#-#.# [007] 60 hepatectomy 60 vertebral fracture 60 OGTT 59 hormone receptor negative 59 trans retinoic acid 59 prognostic markers 59 euthyroid 59 lactate dehydrogenase 59 coronary stenosis 59 pretreatment serum 59 HER2 amplified 59 antitumor effect 59 urine albumin 59 ependymoma 59 pegylated liposomal doxorubicin 59 gastrointestinal stromal tumor GIST 59 inhibitor RG# 59 ovarian cancers 59 tumor necrosis 59 smoldering myeloma 59 Waldenstrom macroglobulinemia 59 mycosis fungoides 59 completely resected 59 chlamydial 59 premalignant lesion 59 Faslodex 59 FDG PET imaging 59 castration resistant prostate cancer 59 biliary stones 59 MYCN amplification 59 poorer prognosis 59 geographic atrophy 59 serum concentrations 59 PHPT 59 Neoadjuvant 59 chlorambucil 59 microalbuminuria 59 D dimer 59 Prostate Specific Antigen PSA 59 CYP#D# genotype 59 mutated K ras 59 androgen suppression therapy 59 albumin excretion 59 confidence interval #.#-#.# 59 endometrial cancer 59 abacavir Ziagen 59 LHRH agonists 59 nonpregnant women 59 anovulatory infertility 59 nonmelanoma skin cancer 59 heavily pretreated patients 59 lobular carcinomas 59 oesophageal adenocarcinoma 59 medullary thyroid cancer 59 Pseudomonas aeruginosa infections 59 MGd 59 cardioembolic stroke 59 lung adenocarcinoma 59 overt nephropathy 59 pulmonary hypertension PH 59 EGFR mutations 59 low expressors 59 ALT flares 59 perimenopausal women 59 cervical dysplasia 59 PAOD 59 ipsilateral breast 59 HCV genotype 59 NPM1 mutation 59 STRIDE PD 59 mCi 59 Clusterin 59 virological response 59 primary aldosteronism 59 prostate specific 59 benign breast 59 myeloproliferative diseases 59 IV malignant melanoma 59 T#I [002] 59 T1DM 59 papillary carcinoma 59 sustained virological response 59 SCCHN 59 metaplasia 59 aromatase inhibitor therapy 59 presymptomatic 59 Chlamydia trachomatis infection 59 Ductal carcinoma 59 multivariate analyzes 59 syngeneic 59 atherogenic dyslipidemia 59 nephrogenic 59 malignant neoplasm 59 gastrointestinal GI cancers 59 pleural mesothelioma 59 hereditary breast cancer 59 postmenopausal breast cancer 59 intraepithelial neoplasia 59 malignancy 59 serum TSH 59 malignant ascites 59 neuroendocrine cancers 59 iniparib BSI 59 BRCA1 mutations 59 Glioblastoma Multiforme 59 postoperative atrial fibrillation 59 TOP2A 59 serum testosterone 59 allogeneic HSCT 59 variceal hemorrhage 59 coinfected patients 59 Hematologic 59 aminotransferases 59 pertuzumab 59 BRCA deficient 59 CTAP# Capsules 59 scintigraphic 59 HRCT 59 gastric cancers 59 demonstrated antitumor activity 59 Acute myeloid leukemia 59 primary hyperparathyroidism 59 histopathologic examination 59 Rectal cancer 59 grade dysplasia 59 thyroid stimulating hormone TSH 59 anthracycline chemotherapy 59 Cytogenetic 59 ductal lobular 59 neoplasms 59 microsatellite instability 59 relapsed AML 59 mTOR inhibitors 59 late onset hypogonadism 59 ischemic lesions 59 MTHFR 59 ERBB2 59 POAG 59 Kaplan Meier analysis 59 rheumatoid factor 59 thermogram 59 lupus nephritis 59 Myelodysplastic syndromes MDS 59 pelvic ultrasound 59 luteinizing hormone releasing 59 pancreatic lung 59 liver transplant recipients 59 colorectal tumors 59 serum urate 59 virological failure 59 colonoscopic 59 myeloproliferative disorder 59 neurological manifestations 59 #F FDG 59 CANCIDAS 59 kidney allograft 59 chronic prostatitis 59 vesicoureteral reflux 59 somatostatin analogs 59 MGUS 59 latent tuberculosis TB 59 gemcitabine Gemzar ® 59 cirrhotic patients 59 PCA3 scores 59 skeletal metastases 59 liver fibrosis 59 ovarian tumor 59 Pemetrexed 59 lymphoproliferative disorders 59 postoperative radiotherapy 59 genotypic resistance 59 acute humoral rejection 59 gastrointestinal stromal tumor 59 Retreatment 59 benign proliferative breast 59 carcinoid tumors 59 logistic regression analysis 59 basal cell nevus syndrome 59 transvaginal ultrasound 59 colorectal cancer 59 BRCA2 mutation 59 subclinical hypothyroidism 59 breast cancer subtypes 59 obstructive CAD 59 B Cell Lymphoma 59 bilateral oophorectomy 59 urine dipstick 59 varicoceles 59 oral Hycamtin 59 Estrogen Receptor 59 lipid abnormalities 59 relapsing remitting MS RRMS 59 myelodysplastic syndrome MDS 59 gastrointestinal malignancies 59 gemcitabine Gemzar 59 invasive coronary angiography 59 core needle biopsy 59 subclinical hyperthyroidism 59 invasive ductal carcinoma 59 contrast induced nephropathy 59 myocardial necrosis 59 Accelerated Partial Breast Irradiation 59 recurrent GBM 59 galiximab 59 squamous cell histology 59 intravesical therapy 59 Glioblastoma Multiforme GBM 59 Immunohistochemical staining 59 assessing T DM1 59 latent tuberculosis infection 59 juvenile idiopathic arthritis 59 pigmented skin lesions 59 transferrin saturation 59 HER2 amplification 59 response pCR 59 cystectomy 59 mycophenolate mofetil 59 hydronephrosis 59 premalignant lesions 59 risk reducing salpingo 59 cerebral microbleeds 59 transgene expression 59 catheter angiography 59 CA# [001] 59 sentinel node 58 MAGE A3 ASCI 58 Subgroup analyzes 58 stage IIIA 58 Liver biopsy 58 GSTP1 58 acute myeloid 58 duplex ultrasonography 58 NRTI resistance 58 TRUS 58 APTIVUS r 58 mammographically 58 esophageal carcinoma 58 curable cancers 58 thrombotic complications 58 transvaginal sonography 58 serum cortisol 58 MALT lymphoma 58 complete cytogenetic response 58 liver histology 58 neutrophil counts 58 radical retropubic prostatectomy 58 gemcitabine carboplatin 58 prospectively defined 58 prolonged QT interval 58 histologies 58 undetectable PSA 58 colorectal pancreatic 58 CK MB 58 molecular abnormalities 58 colorectal carcinomas 58 breast cancers 58 haematologic 58 Cloretazine 58 proliferative diabetic retinopathy 58 thromboembolic complications 58 AA Amyloidosis 58 systolic hypertension 58 Degarelix 58 colorectal cancer liver metastases 58 grade cervical lesions 58 sonographically 58 seminomas 58 lung carcinomas 58 CR CRu 58 Sjögren syndrome 58 p = #.# [003] 58 vWF 58 multivariate logistic regression 58 adjuvant therapies 58 relapsed SCLC 58 nodal dissection 58 hepatic fibrosis 58 Catheter ablation 58 CYT# potent vascular disrupting 58 Hashimoto thyroiditis 58 RECIST Response Evaluation Criteria 58 thromboembolism 58 % CI #.#-#.# [008] 58 candidemia 58 concomitant medications 58 SHPT 58 HIV seropositive 58 seminal vesicle invasion 58 autoantibody 58 multimodality therapy 58 SSc 58 acute aortic dissection 58 hamartoma 58 hypothalamic amenorrhea 58 Subgroup analysis 58 lymphoma subtypes 58 homozygotes 58 stage IIIb IV 58 preoperative staging 58 HBeAg 58 chemo radiotherapy 58 chemoembolization 58 dimeglumine 58 antiestrogen 58 5 Fluorouracil 58 BRAF mutation 58 tamoxifen therapy 58 orchiectomy 58 pretest probability 58 tyrosine kinase inhibitors TKIs 58 chemotherapeutic regimens 58 posttransplant 58 μg liter 58 methylenetetrahydrofolate reductase 58 de novo AML 58 obscure gastrointestinal bleeding 58 cervical neoplasia 58 olaparib 58 Ophena TM 58 follicular thyroid cancer 58 HSCT 58 Response Evaluation Criteria 58 adverse cytogenetics 58 erlotinib Tarceva ® 58 occult metastases 58 cystoscopic 58 intestinal polyps 58 multivariable analysis 58 TMPRSS2 ERG fusion 58 CD4 + cell 58 Her2 58 diagnostic modality 58 axillary nodes 58 histological subtypes 58 lupus anticoagulant 58 Uterine cancer 58 gallstone disease 58 cervical lymph nodes 58 prophylactic oophorectomy 58 clinicopathological 58 malignant pancreatic 58 Surgical excision 58 liposomal doxorubicin 58 atrial arrhythmias 58 upper gastrointestinal bleeding 58 antiretroviral naïve 58 FDG PET scans 58 prognostic marker 58 endoscopic resection 58 Alkaline Phosphatase 58 genomic biomarker 58 LNG IUS 58 atrophic gastritis 58 preoperative radiotherapy 58 adriamycin 58 CT colonography CTC 58 contralateral breast 58 invasive ductal breast cancer 58 PhG alpha 1 58 tipranavir ritonavir 58 uterine tumors 58 chest radiography 58 transitional cell carcinoma 58 docetaxel chemotherapy 58 protease inhibitor PI 58 p# Shc 58 pre menopausal 58 imatinib therapy 58 interferon beta therapy 58 Insulin detemir 58 HER-2/neu 58 excisional biopsy 58 hemodialysis patients 58 adenomatous 58 colon carcinoma 58 PsA 58 albuminuria 58 elevated LDL cholesterol 58 core needle biopsies 58 serum estradiol 58 paclitaxel Taxol 58 percutaneous biopsy 58 polyarticular 58 laser photocoagulation 58 progesterone receptor PR 58 elevated CRP 58 radiosensitivity 58 FGFR2 gene 58 KRAS wild 58 abnormal uterine bleeding 58 Solid Tumours 58 pretargeting 58 carcinoma 58 malignant neoplasms 58 ALA PDT 58 autologous SCT 58 antithyroid 58 hepatic cirrhosis 58 elevated ALT 58 XELOX 58 Cholangiocarcinoma 58 myeloproliferative disorders 58 GIST tumors 58 perioperatively 58 hyperinsulinemic euglycemic clamp 58 primary peritoneal 58 ano genital warts 58 APTIMA HPV 58 varicocele 58 cell lymphoma ALCL 58 LEXIVA r 58 genetic variants associated 58 conditional logistic regression 58 salpingo oophorectomy 58 Her2 positive 58 clinically evaluable 58 FSAD 58 benign prostatic hypertrophy BPH 58 elevated LDH 58 FOLPI 58 Non inferiority 58 NMP# 58 DXA scan 58 AVODART 58 spiral computed tomography 58 adjuvant cisplatin 58 acute myelogenous leukemia AML 58 troponin T 58 pituitary adenomas 58 histologic 58 transarterial 58 hypogonadal 58 tumoral 58 antiandrogens 58 fluvastatin 58 gynecologic cancers 58 postoperative mortality 58 gastrointestinal stromal tumors 58 tibolone 58 virologic responses 58 melphalan prednisone 58 VA# [002] 58 QTc prolongation 58 malignancies 58 univariate analysis 58 HBeAg positive patients 58 metastatic cancer 58 transfusion syndrome 58 lymphovascular invasion 58 μmol L 58 SCr 58 metastatic neuroendocrine tumors 58 chronic GVHD 58 exemestane Aromasin 58 Multivariate logistic regression 58 inhibin 58 hyperplasia BPH 58 intratumoral 58 5-fluorouracil/leucovorin 58 carcinomatosis 58 IDH1 mutation 58 SSc patients 58 transabdominal 58 myelodysplastic myeloproliferative diseases 58 relapsing multiple sclerosis 58 PARP inhibitor